ClinicalTrials.gg
Sign In

Carcinoma, Transitional Cell clinical trials

The registry lists 633 studies for Carcinoma, Transitional Cell across more than 10 countries. 181 are recruiting or about to start. 337 of them are mainly about Carcinoma, Transitional Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

ClinicalTrials.gov finds 1,163 studies for Carcinoma, Transitional Cell. How that becomes 633 here

This page counts the studies the registry files under Carcinoma, Transitional Cell, and those it files under no condition that list Carcinoma, Transitional Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,163Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −56List Carcinoma, Transitional Cell as a condition, but the registry did not file them under itMost often written as “Transitional Cell Carcinoma of the Bladder” (24), “Fallopian Tube Transitional Cell Carcinoma” (20), and “Ovarian Transitional Cell Carcinoma” (17). The registry filed them under other conditions only, most often Urinary Bladder Neoplasms (27) and Fallopian Tube Neoplasms (18).
  3. −474Match it another way54 name it in the title, 60 in a keyword, and 360 by a synonym or other text the search reads.
  4. 633The count on this page12 of them list Carcinoma, Transitional Cell in their own words; the registry filed them under no condition.

Get an email when these change. Save the Carcinoma, Transitional Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
204
Recruiting
147
Terminated
93
Active, not recruiting
78
Status unknown
51
Not yet recruiting
27

Phase

Phase 2
293
Phase 1
208
Phase 3
49
Early Phase 1
13
Phase 4
3

Where

United States
361
China
88
Spain
79
France
70
Canada
61
Italy
60

Who runs them

National Cancer Institute (NCI) (25) · M.D. Anderson Cancer Center (14) · Memorial Sloan Kettering Cancer Center (12) · Pfizer (11) · UroGen Pharma Ltd. (10) · Fox Chase Cancer Center (9) · National Taiwan University Hospital (9) · Hoffmann-La Roche (8)

What is being tested here

Drugs under test in Carcinoma, Transitional Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Enfortumab vedotin10120
Pembrolizumab8327
Disitamab vedotin5210
Nivolumab4116
Avelumab4314
Sacituzumab govitecan419
Gemcitabine3326
Toripalimab327
Gallium-68313
Mitomycin2611

Drug classes tested here Immune checkpoint inhibitors 30 open · Antibody-drug conjugates (ADCs) 22 open · Tyrosine kinase inhibitors (TKIs) 8 open · Antimetabolites 5 open · Alkylating agents 3 open

Coming up

23phase 3 studies under way
89studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger. 4 (3%) take children under 18. 2 (1%) are for women only and 1 (1%) for men only; 8 (5%) take healthy volunteers.

Recruiting studies that take each age, of 147
AgeWomenMen
103 (2%)3 (2%)
18139 (95%)137 (93%)
30142 (97%)141 (96%)
40143 (97%)142 (97%)
50145 (99%)144 (98%)
65146 (99%)145 (99%)
75144 (98%)143 (97%)
85129 (88%)128 (87%)

Across all 633 studies, recruiting or not: 5% stop at 75 or younger and <1% at 65; 4% take children; 1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Transitional Cell studies take

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 144 mo31–63 · 99 studies44 mo34–57 · 62 studies48 mo26–73 · 37 studies
Phase 1/264 mo49–224 · 48 studies——
Phase 257 mo35–102 · 119 studies—59 mo40–102 · 91 studies
Phase 356 mo24–111 · 28 studies——
Interventional, no phase58 mo23–… · 28 studies——
Observational56 mo27–… · 60 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting2

Results posted3

Stopped1

Newly registered3

Studies

Recruiting first, then most recently updated. Showing 50 of 633. Browse all 633 → or search them.